CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


BI 764198Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug1050 Exposure Therapy Wiki 1.00
drug1690 Matching placebo Wiki 0.58

Correlated MeSH Terms (9)


Name (Synonyms) Correlation
D009155 Mutism NIH 1.00
D009771 Obsessive-Compulsive Disorder NIH 0.71
D001010 Anxiety, Separation NIH 0.71
D000072861 Phobia, Social NIH 0.71
D003193 Compulsive Personality Disorder NIH 0.71
D000379 Agoraphobia NIH 0.71
D016584 Panic Disorder NIH 0.58
D004194 Disease NIH 0.17
D001008 Anxiety Disorders NIH 0.15

Correlated HPO Terms (3)


Name (Synonyms) Correlation
HP:0002300 Mutism HPO 1.00
HP:0000756 Agoraphobia HPO 0.71
HP:0000722 Obsessive-compulsive behavior HPO 0.58

There is one clinical trial.

Clinical Trials


1 Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 764198 in Healthy Male Subjects (Double-blind, Randomised, Placebo-controlled, Parallel Group Design) and Effect of Food on the Relative Bioavailability of BI 764198 (Open-label, Randomised, Two-way Cross-over)

To investigate safety and tolerability of BI 764198 in healthy male subjects following oral administration of multiple rising doses per day over 14 days and to investigate the food effect on the relative bioavailability of BI 764198.

NCT04102462 Healthy Drug: BI 764198 Drug: Matching placebo

Primary Outcomes

Measure: percentage of subjects with drug-related adverse events

Time: Up to Day 34

Secondary Outcomes

Measure: MRD Part - AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ)

Time: Up to Day 34

Measure: MRD Part -Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ)

Time: Up to Day 34

Measure: MRD Part -tmax,ss (time from last dosing to maximum concentration of the analyte in plasma at steady state)

Time: Up to Day 34

Measure: FE Part - AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)

Time: Up to Day 17

Measure: FE Part - Cmax (maximum measured concentration of the analyte in plasma)

Time: Up to Day 17

Measure: FE Part - tmax (Time from (last) dosing to the maximum measured concentration of the analyte in plasma)

Time: Up to Day 17


No related HPO nodes (Using clinical trials)